inotiv
analyze. answer. advance.

Oncology
Cell Line: KYSE-30

Esophageal Squamous Cell Carcinoma
Xenograft Tumor Model

MODEL	NOMENCLATURE	HAIR	T CELLS	B CELLS	NK CELLS
SHrN®	NOD.Cg-$Prkdc^{scid}Hr^{hr}$/NCrHsd	No	Nonfunctional	Nonfunctional	Impaired

MODEL

The SHrN® is a Hairless NOD.SCID Mouse developed by Harlan. Harlan became Envigo in 2015, then Envigo was acquired by Inotiv in 2021. The SHrN® is a triple-immunodeficient model with distinct benefits and excellent for tumor xenografts.

CELL LINE

Human KYSE-30 cells sourced from DSMZ® (Number: ACC 351) were implanted into a cohort of SHrN® mice. Female mice at approximately 8 weeks of age were implanted with 5.0e6 cells with GFR Matrigel (1:1 dilution) into the subcutaneous space of the right flank.space of the right flank.

TUMOR GROWTH *IN VIVO*

The mice were maintained in a barrier under controlled environmental conditions. The mice consumed Teklad Global Rodent Diet 2914 (14% protein). Body weights were taken and tumor measurements were assessed with a caliper twice per week.

Tumor Growth Rate for KYSE-30 Cells Inoculated into Female SHrN® Mice

Data shown as mean values; N=10
Tumor growth study services conducted by Labcorp Drug Development

800.793.7287 | RMSinfo@inotivco.com

inotivco.com